MTAA CEO sheds light on policy and advocacy focus for 2024

MedTech & Diagnostics News: In this Health Industry Hub interview, Ian Burgess, CEO of MTAA, acknowledged the top highlights that led to meaningful change in 2023, and voiced the key policy agenda for the new year.

The interview highlighted the intense consultation process surrounding the Prescribed List (PL) and private health insurance reforms, emphasising their significance for the medtech sector. Mr Burgess touched upon the potential challenges posed by an early federal election and underscored the factors that will determine success of the reforms.

Environmental sustainability emerged as a strategic focus for the medtech sector, driven by increasing pressures and interest from stakeholders such as surgeons, hospitals, and policy makers. The first National Health and Climate Strategy also aims to establish green procurement guidelines. MTAA’s role and advocacy objectives in supporting the industry through the evolving changes was highlighted.

Nurturing innovation and ensuring supply chain resilience were identified as additional priority areas for the medtech sector. Mr Burgess delved into the obstacles that still need to be overcome to make progress in these areas.

Looking ahead, the interview explored the main complexities and uncertainties expected to impact the medtech sector this year. Mr Burgess outlined how these challenges correlate with MTAA’s policy and advocacy plans, providing insights into the industry body’s strategic approach to addressing the evolving landscape of the medtech industry in 2024.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.